Either pharma bro Martin Shkreli is actually trying to threaten Ghostface Killah, or April Fool's Day is here really early this year

Before you go, we thought you'd like these...


Martin Shkreli -- Shut Your Mouth Ghostface Killah ... My Goons Will Take You Out!!

This week in bad ideas, it appears that human social experiment Martin Shkreli, excessively proud owner of Once Upon a Time in Shaolin, has tried to threaten and demand an apology from Ghostface Killah. The so-called beef stems from recent interviews in which Ghost mocked Shkreli and called him out for price-gouging and album-bogarting.

"It's just one of these things, that for whatever reason you think it's okay to beef with me, but that's a big mistake," Shkreli says in the above video, before fishing for a pen pal. "If you ever say some dumb shit again, this album, this Shaolin, I'm gonna erase all your shit from this album. I'm gonna erase you from the record books of rap. You're my son. You have to listen to me. I butter your bread, you understand me? Without me, you're nothing."

The new dad also (kind of) explained the situation to TMZ, in yet another Thursday video sure to (re-)insult music fans the world over:

Martin Shkreli -- You Dissing Me, TMZ?!

Ghost had yet to respond at time of publication, but Shkreli was not backing down:

Where's NDGT, dangerous beef executioner, when you need him?

More on Shkreli:

18 PHOTOS
Pharma CEO Martin Shkreli
See Gallery
Either pharma bro Martin Shkreli is actually trying to threaten Ghostface Killah, or April Fool's Day is here really early this year
Pharmaceutical chief Martin Shkreli, right, huddles with his attorney Benjamin Brafman on Capitol Hill in Washington, Thursday, Feb. 4, 2016, following his appearance before the House Committee on Oversight and Reform Committee. Shkreli refused to testify before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired. (AP Photo/Susan Walsh)
Benjamin Brafman, right, attorney for pharmaceutical chief Martin Shkreli, foreground, speaks on Capitol Hill in Washington, Thursday, Feb. 4, 2016, during a House Committee on Oversight and Reform Committee hearing on rising drug prices. Shkreli refused to testify before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired. (AP Photo/Susan Walsh)
Pharmaceutical chief Martin Shkreli waits on Capitol Hill in Washington, Thursday, Feb. 4, 2016, for the start of the House Committee on Oversight and Reform Committee hearing on his former company's decision to raise the price of a lifesaving medicine. Shkreli refused to testify before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired. (AP Photo/Susan Walsh)
Pharmaceutical chief Martin Shkreli waits on Capitol Hill in Washington, Thursday, Feb. 4, 2016, for the start of the House Committee on Oversight and Reform Committee hearing on his former company's decision to raise the price of a lifesaving medicine. Shkreli refused to testify before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired. (AP Photo/Susan Walsh)
Former Turing Pharmaceuticals CEO Martin Shkreli, center, listens as his lawyer Benjamin Brafman, left, speaks to reporters as they leave court in New York, Wednesday, Feb. 3, 2016. Shkreli, who has become the poster child of pharmaceutical-industry greed after hiking the price of an anti-infection drug by more than 5,000 percent, is scheduled to appear at a congressional hearing on Thursday. (AP Photo/Seth Wenig)
Martin Shkreli, chief investment officer of MSMB Capital Management, sits for a photograph in his office in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
FILE - In this Thursday, Dec. 17, 2015, file photo, Martin Shkreli, center, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is escorted by law enforcement agents in New York after being taken into custody following a securities probe. U.S. Rep. Elijah Cummings, D-Maryland, said a lawyer for Shkreli indicated he has not sought permission from a New York judge to appear at a congressional hearing Tuesday, Jan. 26, 2016, on drug prices, despite receiving a subpoena. (AP Photo/Craig Ruttle, File)
Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is belted into an awaiting car after being taken into custody following a securities probe, on Thursday, Dec. 17, 2015 in New York. A seven-count indictment unsealed in Brooklyn federal court Thursday charged Shkreli with conspiracy to commit securities fraud, conspiracy to commit wire fraud and securities fraud. (AP Photo/Craig Ruttle)
Martin Shkreli, center, leaves the courthouse after his arraignment in New York, Thursday, Dec. 17, 2015. Shkreli, the former hedge fund manager vilified in nearly every corner of America for buying a pharmaceutical company and jacking up the price of a life-saving drug more than fiftyfold, was arrested Thursday on securities fraud charges unrelated to the furor. (AP Photo/Seth Wenig)
Martin Shkreli, chief investment officer of MSMB Capital Management, sits behind a chess board in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
Martin Shkreli, chief investment officer of MSMB Capital Management, works on a computer in his office in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
"THEY SEE ME ROLLING..." http://t.co/D1mDBEeZMq
Turing Pharma Puppy Party 2015 http://t.co/0xf1zKUYXy
Activists hold signs containing the image of Turing Pharmaceuticals CEO Martin Shkreli in front the building that houses Turing's offices, in New York, Thursday, Oct. 1, 2015, during a protest highlighting pharmaceutical drug pricing. Turing Pharmaceuticals sparked an angry backlash last month after it raised the price of Daraprim, the only approved treatment for a rare, life-threatening parasitic infection, by more than 5,000 percent. (AP Photo/Craig Ruttle)
FILE - In this Thursday, Oct. 1, 2015, file photo, carrying an image of Turing Pharmaceuticals CEO Martin Shkreli in a makeshift cat litter pan, AIDS activists and others are asked to leave the lobby of 1177 6th Ave. in New York, during a protest highlighting pharmaceutical drug pricing. A Senate committee tasked with protecting seniors launched an investigation Wednesday, Nov. 4, 2015, into drug price hikes by Turing, Valeant Pharmaceuticals, Retrophin Inc. and Rodelis Therapeutics, responding to public anxiety over rising prices for critical medicines. (AP Photo/Craig Ruttle, File)
Activists hold signs containing the image of Turing Pharmaceuticals CEO Martin Shkreli in front the building that houses Turing's offices, in New York, Thursday, Oct. 1, 2015, during a protest highlighting pharmaceutical drug pricing. Turing Pharmaceuticals sparked an angry backlash last month after it raised the price of Daraprim, the only approved treatment for a rare, life-threatening parasitic infection, by more than 5,000 percent. (AP Photo/Craig Ruttle)
Activists hold signs containing the image of Turing Pharmaceuticals CEO Martin Shkreli in front the building that houses Turing's offices, in New York, Thursday, Oct. 1, 2015, during a protest highlighting pharmaceutical drug pricing. Turing Pharmaceuticals sparked an angry backlash last month after it raised the price of Daraprim, the only approved treatment for a rare, life-threatening parasitic infection, by more than 5,000 percent. (AP Photo/Craig Ruttle)
of
SEE ALL
BACK TO SLIDE
SHOW CAPTION +
HIDE CAPTION


More from Vulture:
Watch the Video for Zayn Malik's First Solo Single, 'Pillowtalk'
Stephen Colbert Moderates a Debate Between Donald Trump and the Man Who Disagrees With Him on Everything, Donald Trump
Watch Jay Leno Prank Someone Who's Trying to Prank Him

Read Full Story

People are Reading